| Literature DB >> 26444095 |
David K Simon1, Tanya Simuni2, Jordan Elm3, Joanne Clark-Matott1, Allison K Graebner1, Liana Baker4, Susan R Dunlop5, Marina Emborg6, Cornelia Kamp7, John C Morgan8, G Webster Ross9, Saloni Sharma4, Bernard Ravina10.
Abstract
Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.Entities:
Keywords: 8-hydroxydeoxyguano sine; 8OHdG; IL-6; PGC-1alpha; Parkinson’s disease; biomarker; cytokine; inflammation; interleukin-6; oxidative stress; pioglitazone
Mesh：
Substances：
Year: 2015 PMID： 26444095 PMCID： PMC5061495 DOI： 10.3233/JPD-150666
Source DB: PubMed Journal: J Parkinsons Dis ISSN： 1877-7171 Impact factor: 5.568